Van ECK Associates Corp Cuts Stock Position in Corteva, Inc. $CTVA

Key Points

• VanECK reduced its Corteva stake by 62.6% in the 3rd quarter, selling 3,024,639 shares and retaining 1,808,962 shares (about 0.27% of the company) valued at $122.34 million.
• Corteva reported quarterly EPS of $0.22 (in line with estimates) but missed on revenue ($3.91B vs. $4.23B expected) and set FY2026 guidance of 3.45–3.70 EPS.
• Analyst sentiment is mixed but the consensus is a “Moderate Buy” with a $82.90 target; RBC and Wells Fargo raised price targets (to $89 and $85) while UBS and others moved to Hold/Neutral.

Van ECK Associates Corp reduced its stake in Corteva, Inc. (NYSE:CTVA - Free Report) by 62.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,808,962 shares of the company's stock after selling 3,024,639 shares during the period. Van ECK Associates Corp owned approximately 0.27% of Corteva worth $122,340,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in CTVA. Bank of Montreal Can grew its stake in shares of Corteva by 3.0% in the third quarter. Bank of Montreal Can now owns 678,799 shares of the company's stock valued at $45,907,000 after buying an additional 19,478 shares in the last quarter. Legal & General Group Plc grew its position in Corteva by 14.3% in the third quarter. Legal & General Group Plc now owns 5,753,982 shares of the company's stock valued at $389,142,000 after acquiring an additional 720,469 shares in the last quarter. Banque Cantonale Vaudoise raised its stake in shares of Corteva by 41.6% during the third quarter. Banque Cantonale Vaudoise now owns 4,110 shares of the company's stock valued at $278,000 after purchasing an additional 1,208 shares during the period. Fieldview Capital Management LLC acquired a new position in shares of Corteva during the third quarter worth $4,790,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Corteva in the third quarter valued at $5,704,000. 81.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on CTVA. Royal Bank Of Canada lifted their price target on shares of Corteva from $80.00 to $89.00 and gave the stock an "outperform" rating in a research note on Thursday, February 5th. UBS Group lowered Corteva from a "buy" rating to a "hold" rating in a research report on Monday, February 9th. Rothschild & Co Redburn reduced their price target on Corteva from $71.00 to $65.00 and set a "neutral" rating for the company in a report on Tuesday, November 11th. Wall Street Zen lowered Corteva from a "buy" rating to a "hold" rating in a research note on Saturday, February 7th. Finally, Wells Fargo & Company lifted their price objective on Corteva from $77.00 to $85.00 and gave the stock an "overweight" rating in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Corteva currently has a consensus rating of "Moderate Buy" and a consensus target price of $82.90.

Corteva Price Performance

Shares of CTVA opened at $76.30 on Wednesday. The stock has a 50 day moving average of $73.40 and a 200-day moving average of $69.06. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. Corteva, Inc. has a 52 week low of $53.40 and a 52 week high of $80.90. The firm has a market cap of $51.31 billion, a price-to-earnings ratio of 48.29, a PEG ratio of 2.68 and a beta of 0.72.

Corteva (NYSE:CTVA - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. Corteva's quarterly revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, analysts forecast that Corteva, Inc. will post 2.96 EPS for the current year.

Corteva Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be paid a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Monday, March 2nd. Corteva's dividend payout ratio is presently 45.57%.

Insider Activity

In other news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.15% of the company's stock.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.